| Autor: |
Keum Hwa Lee, Sung Hwi Hong, Jinhae Jun, Youngheun Jo, Woogyeong Jo, Dayeon Choi, Jeongho Joo, Guhyun Jung, Sunghee Ahn, Andreas Kronbichler, Michael Eisenhut, Jae Il Shin |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Clinical and Experimental Pediatrics, Vol 63, Iss 5, Pp 158-163 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
2713-4148 |
| DOI: |
10.3345/kjp.2019.00514 |
| Popis: |
IgA vasculitis, formerly known as Henoch-Schönlein purpura, is a systemic IgA-mediated vasculitis of the small vessels commonly seen in children. The natural history of IgA vasculitis is generally self-limiting; however, one-third of patients experience symptom recurrence and a refractory course. This systematic review examined the use of dapsone in refractory IgA vasculitis cases. A literature search of PubMed databases retrieved 13 articles published until June 14, 2018. The most common clinical feature was a palpable rash (100% of patients), followed by joint pain (69.2%). Treatment response within 1–2 days was observed in 6 of 26 patients (23.1%) versus within 3–7 days in 17 patients (65.4%). Relapse after treatment discontinuation was reported in 17 patients (65.4%) but not in 3 patients (11.5 %). Four of the 26 patients (15.4%) reported adverse effects of dapsone including arthralgia (7.7%), rash (7.7%), and dapsone hypersensitivity syndrome (3.8%). Our findings suggest that dapsone may affect refractory IgA vasculitis. Multicenter randomized placebo-controlled trials are necessary to determine the standard dosage of dapsone at initial or tapering of treatment in IgA vasculitis patients and evaluate whether dapsone has a significant benefit versus steroids or other medications. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
